

BioNovelus	For the Three	For the Twelve
Balance Sheet	Months Ended	Months Ended
	September 30,2015	September 30,2014
Assets		
Cash	$ 228.32	$ 100.00
Accounts Receivable	$ 3,600.00	$ 15,511.00
Intellectual Property	$ 500,000.00	$ 29,632.00
Property & Equipment - Intellectual	$ 1,698,140.00	$ -
Prepaid expenses	$ 550,000.00	$ -
Less Deprec	$ (1,095,210.74)	$ -
Total Assets	$ 1,656,757.58	$ 45,243.00
Liabilities and Shareholder's Deficiency		
Accounts Payable	$ 9,297.81	$ 957.00
Accrued director fees	$ 637,500.00	$ 510,000.00
Accrued legal fees	$ -	$ -
Testing	$ 7,820.50	
Loan payable to officers	$ 71,950.01	$ -
Loan payable to officers (Salaries)	$ 45,000.00	$ -
Notes payable-Promissory Note	$ 361,637.00	$ 575,514.00
Total Liabilities	$ 1,133,205.32	$ 1,086,471.00
Preferred stock, $.001 par value,10,000,000 shares	$ 10,000.00	$ 10,000.00
authorized; 9,800,000. shares issued and outstanding		
Common stock, $.001 par value 500,000.000 shares		
authorized and 86,917,656 shares and 70,116,467	$ 70,116.00	$ 86,918.00
shares issued and outstanding as of June 30, 2015		
and Sept 30,2014 respectively,		
Additional paid in capital	$ 2,829,231.00	$ 2,829,231.00
Accumulated Deficit	$ (2,847,891.00)	$ (4,057,863.00)
Total Shareholders's Equity	$ 566,812.26	$ (1,131,714.00)
Reserve		
Total Liabilities and Shareholders Deficiency	$ 1,681,357.58	$ (45,243.00)
See Accompanying notes		

BioNovelus		
Income Statement		
	For the Three Months Ended September 30,2015	For the Twelve Months Ended September 30,2014
Revenue	$ -	$ -
Expenses		
Travel	$ 767.20	$ -
Advertising & Promotion	$ 646.68	$ -
Bank Fees	$ 119.97	$ -
Licenses & Permit	$ 800.00	$ -
Consulting Fees	$ 1,130.77	$ -
Mail Service	$ 47.72	$ -
Meal & Entertainment	$ 782.95	$ 195,875.00
Research And Development	$ 1,500.00	
SCC & OTC Filing	$ -	
Professional Fees	$ 275.00	
Stock Management	$ 1,545.00	
Subscription	$ 30.00	
Cleaning	$ 32.60	
Computer and Internet Expenses	$ 171.02	
Lab testing	$ 4,250.00	
Auto Expense	$ 960.57	
Office Supplies	$ 360.52	
Total Expenses	$ 13,420.00	$ 195,875.00
Loss from Continuing Operations	$ (13,420.00)	$ (195,875.00)
Other Income (Expenses)		
	$ -	$ -
Total Other Income (Expenses)	$ -	$ -
Net Loss	$ (13,420.00)	$ (195,875.00)

BioNovelus				
Statement of Cash Flows				
		For the Three		For the Twelve
		Months Ended		Months Ended
		September 30,2015		September 30,2014
Cash Flows from operating and activities of discounted operations				
Net Loss		$ (13,420.00)		$ (35,919.00)
Adjustments to reconcile net loss to net cash				
Used in) provided by operating activies				
Accounts Payable				$ (127,513.00)
Current Liability				$ -
Accrued Expenses		$ -		$ -
Accounts Receivable		$ -		$ (13,375.00)
Note payable-Officer		$ (45,000.00)		$ -
Net cash(used) provided by operating activites				$ (176,807.00)
Cash flows from investing activites of discounted operations				
Purchase of property and equipment		$ -		$ -
Net cash used in investing activies		$ -		$ -
Preferred stock		$ -		$ -
Common Stock		$ -		$ -
Additional Paid-in capital		$ -		$ -
Repayments of long-term debt to equity				$ 176,807.00
Net cash provided by (used in) financing activies		$ (9,299.91)		$ 176,807.00
Net (Decrease) increase in cash		$ (13,420.00)		$ -
Cash at beginning of period		**$ 7,689.00**		$ -
Cash at end of period		**$ 228.32**		$ -



BioNovelus							
Statement of StockHolders Equity						Retained	
	Preferred Stock		Common Stock		Additional	Earnings	
					Paid in	Accumulated	
					Capital	deficit	Total
Balance , March 30, 2015	10,000.00	10,000.00	86,917,656.00	86,918.00	2,829,231.00	(3,181,843.00)	(255,694.00)
Return to Treasury - Stock Split			-86,801,765	-86801			
Issued From Treasury - Acquisition			70,000,000.00	70,000.00			
Issued from Treasury - Rounding			576.00	-			
Balance, June 30, 2015	10,000.00	9,800,000.00	70,116,467.00	70,117.00	2,829,231.00	(2,747,891.00)	1,188,818.26
Balance, Sept 30, 2015	10,000.00	9,800,000.00	70,116,467.00	70,117.00	2,829,231.00	(2,747,891.00)	1,188,818.26